Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

Janeen H. Trembley, Gretchen M. Unger, Vicci L. Korman, Diane K. Tobolt, Zygmunt Kazimierczuk, Lorenzo A. Pinna, Betsy T. Kren, Khalil Ahmed

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

CK2, a pleiotropic Ser/Thr kinase, is an important target for cancer therapy. We tested our novel tenfibgen-based nanocapsule for delivery of the inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1. H-benzimidazole (DMAT) and an siRNA directed against both CK2α and α' catalytic subunits to prostate cancer cells. We present data on the TBG nanocapsule itself and on CK2 inhibition or downregulation in treated cells, including effects on Nuclear Factor-kappa B (NF-κB) p65. By direct comparison of two CK2-directed cargos, our data provide proof that the TBG encapsulation design for delivery of drugs specifically to cancer cells has strong potential for small molecule- and nucleic acid-based cancer therapy.

Original languageEnglish (US)
Pages (from-to)48-58
Number of pages11
JournalCancer Letters
Volume315
Issue number1
DOIs
StatePublished - Feb 1 2012

Keywords

  • CK2
  • DMAT
  • Nanocapsule
  • Nanoparticle
  • Prostate cancer
  • Tenfibgen

Fingerprint Dive into the research topics of 'Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells'. Together they form a unique fingerprint.

Cite this